Y-27632 Dihydrochloride: Selective ROCK1/2 Inhibitor for Cytoskeletal and Cancer Research

Executive Summary: Y-27632 dihydrochloride is a small-molecule inhibitor that targets ROCK1 and ROCK2 with nanomolar potency, exhibiting over 200-fold selectivity against other kinases (ApexBio). It disrupts Rho-mediated stress fiber formation and cytokinesis, and is widely used to enhance stem cell viability and suppress tumor invasion (Ren et al. 2025). Y-27632 is highly soluble in DMSO and water, supporting flexible experimental design. Benchmarked studies confirm its ability to reduce prostatic smooth muscle proliferation and block RhoA/ROCK-driven cellular responses. Its selectivity and robust performance make it a preferred option for dissecting ROCK pathway biology in vitro and in vivo.

Biological Rationale

Rho-associated protein kinases (ROCK1 and ROCK2) are serine/threonine kinases that mediate the effects of RhoA GTPase on the actin cytoskeleton. Activation of the Rho/ROCK pathway is pivotal for cellular processes such as actomyosin contractility, stress fiber formation, cell migration, and cytokinesis (Ren et al. 2025). Dysregulated ROCK signaling has been implicated in cancer cell invasion, metastasis, fibrotic diseases, and stem cell apoptosis. Thus, selective inhibition of ROCK1/2 is a validated approach for studying cytoskeletal dynamics, cell proliferation, and tumor biology.

Mechanism of Action of Y-27632 dihydrochloride

Y-27632 dihydrochloride binds to the catalytic domains of ROCK1 (IC₅₀ ≈ 140 nM) and ROCK2 (K_i ≈ 300 nM), competitively inhibiting ATP binding and kinase activity (ApexBio). This action prevents phosphorylation of downstream targets such as myosin light chain 2 (MLC2), thereby blocking actomyosin contractility. Inhibition leads to disruption of Rho-mediated stress fiber assembly, altered focal adhesion turnover, and impaired cytokinesis. Y-27632 displays >200-fold selectivity over closely related kinases—including PKC, PKA, MLCK, and PAK—minimizing off-target effects. It is cell-permeable and exerts effects at low micromolar concentrations in cell-based assays.

Evidence & Benchmarks

• Y-27632 inhibits ROCK1 kinase activity with an IC₅₀ of 140 nM under in vitro conditions (ApexBio).
• It reduces prostatic smooth muscle cell proliferation in a concentration-dependent manner (ApexBio).
• In mouse models, Y-27632 suppresses tumor invasion and metastasis, diminishing pathological structures (Ren et al. 2025).
• ROCK inhibition by Y-27632 restores tight junction integrity and reduces viral infection in vitro (Ren et al. 2025).
• Y-27632 demonstrates >200-fold selectivity versus PKC, MLCK, and PAK in kinase profiling assays (ApexBio).
• High solubility: ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, ≥52.9 mg/mL in water at 25°C (ApexBio).

Applications, Limits & Misconceptions

Y-27632 dihydrochloride is widely used in stem cell biology, cancer research, and studies of cytoskeletal dynamics. It enhances hESC and iPSC survival post-dissociation, reduces anoikis, and is a standard additive in single-cell passaging protocols. In oncology, it is used to dissect mechanisms of tumor cell invasion and metastasis by selectively blocking ROCK-mediated motility. The compound also facilitates studies of tight junction regulation and viral entry, as demonstrated in MVC infection models (Ren et al. 2025).

This article expands upon previous reviews such as Y-27632 Dihydrochloride: Precision ROCK Inhibitor for Cyt..., which focused on cytoskeletal modulation, by providing updated peer-reviewed evidence and specific workflow benchmarks. For application-specific troubleshooting and advanced workflows, see Y-27632 Dihydrochloride: Selective ROCK Inhibition for Advanced Assays, which offers practical guidance for experimental design. This article further clarifies distinctions in selectivity and mechanism compared to broader kinase inhibitors.

Common Pitfalls or Misconceptions

• Y-27632 does not inhibit all Rho-family GTPase pathways; it is selective for ROCK1/2.
• Long-term storage of aqueous solutions leads to degradation; only store stock solutions below -20°C for several months.
• It does not reverse all types of cell death; its pro-survival effects are context-dependent (e.g., stem cell dissociation, not apoptosis from DNA damage).
• Y-27632 is not suitable for in vivo therapeutic use; it is for research applications only.
• Off-target effects may occur at >10 μM; use the lowest effective concentration for specificity.

Workflow Integration & Parameters

Y-27632 dihydrochloride is supplied as a solid and should be desiccated and stored at 4°C or below. For optimal solubility, dissolve at ≥111.2 mg/mL in DMSO, ≥17.57 mg/mL in ethanol, or ≥52.9 mg/mL in water, with gentle warming (37°C) or ultrasonic bath if needed. Prepare aliquots and store below -20°C; avoid repeated freeze-thaw cycles. In cell culture, recommended working concentrations range from 1 μM to 10 μM, depending on cell type and assay. Replace medium containing Y-27632 every 24–72 hours for longer-term experiments. For cytoskeletal studies, pre-incubate cells for 30–60 min prior to analysis. Always include vehicle-only controls to confirm specificity.

Conclusion & Outlook

Y-27632 dihydrochloride (A3008) is a robust, selective inhibitor of ROCK1/2 signaling, enabling high-precision studies in cell biology, oncology, and stem cell research. Its favorable solubility and selectivity profile allow for reproducible, context-specific modulation of cytoskeletal dynamics and cellular proliferation. Future research may expand its application in viral entry models, organoid culture, and regenerative medicine workflows. For detailed product specifications and ordering, refer to the Y-27632 dihydrochloride product page.